Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LP-118 |
Synonyms | |
Therapy Description |
LP-118 inhibits BCL2 and BCL-XL, potentially leading to apoptosis of tumor cells and reduced tumor growth (Blood (2021) 138 (Supplement 1): 679). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LP-118 | LP 118|LP118 | BCL-XL inhibitor 14 BCL2 inhibitor 27 | LP-118 inhibits BCL2 and BCL-XL, potentially leading to apoptosis of tumor cells and reduced tumor growth (Blood (2021) 138 (Supplement 1): 679). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |